There are many new immunotherapeutic drugs for cancer in the research pipeline. Too few patients are available to fill the clinical trials,  as many are receiving treatment from physicians outside of the research institutions where trials are being held. In addition, many pharmaceutical companies are researching similar drugs, meaning there can be significant competition for the patients who are available. How should this problem be solved?